Scalper1 News
Development-stage biotech Infinity Pharmaceuticals (INFI) landed a key deal to develop its blood cancer drug duvelisib in partnership with big pharma AbbVie (ABBV), sending Infinity stock up 46% to a six-month high near 16 on the stock market today. The AbbVie-Infinity collaboration includes an upfront payment of $275 million, and up to $530 million in milestone payments if duvelisib passes successfully through development, approval and launch. Scalper1 News
Scalper1 News